SkinBit

About the offering

SkinBit - Al-Powered Skin Screening for Everyone Investor overview Skin cancer touches 3.6M Americans yearly-75% of all cancer diagnoses-yet our healthcare system is catastrophically failing them. Only 48 million appointment slots exist for 98 million who need screening, and doctors miss 3 out of 10 cancers. SkinBit's revolutionary whole body AI scanner achieves 90% accuracy in 60 seconds, transforming both access and outcomes." 3 Key Reasons to Invest in SkinBit Untapped $15B Market with Guaranteed Demand: Dermatologist shortages worsen yearly while skin cancer rates climb. By 2030, half of all dermatology needs will go unmet. Our scanner-as-a-service approach eliminates partner investment risk, allowing rapid expansion throughout the US. Tadnt IadianATDufa muusry-LeaUig AI renomance: uul wHOlE DOuy scaшет in development targets 95% accuracy, surpassing traditional dermatologist exams (75%) thanks to our proprietary 50,000 data set. Proven Team Executing Against Desperate Need: CEO survived melanoma and built two successful exits, including public company Deezer. Stanford's Chief of Dermatology provides clinical validation. With 2,000 waitlist signups in three weeks and zero marketing spend, market demand is confirmed. This team knows how to scale healthcare technology profitably. Why I Started SkinBit: My Battle with Melanoma "Half of Americans who need skin cancer screening can't get it. As someone who survived melanoma, I couldn't ignore a problem this big with a solution this clear." Jonathan Benassaya CEO & Founder SKINBIT In 2020, my dermatologist almost missed the melanoта. After inconclusive initial biopsy results and weeks of agonizing uncertainty-where every passing day felt like a lifetime-I faced removing a 2.5cm circle from my face for a 3mm spot-risking permanent disfigurement. This experience showed me that dermatology needs transformation." - СЕО, Jonathan Benassaya The Dermatology Crisis: Millions Left Waiting Skin cancer affects 3.3 million Americans annually, resulting in 5.4M diagnoses, with many waiting up to 12 months to see a dermatologist. It is estimated that by 2030, half of all dermatology needs will go unmet due to specialist shortages. The current standard relies on subjective visual examinations without data tracking, translating to 25% of false negatives (i.e., patients with cancer missed by their dermatologists) and up to 40% of false positives (i.e., patients with benign lesions treated ror cancers) (source) 5.4M 25% 40% Annual skin Cancer Diagnoses (1) False Negative (2) False Positive (2) Unserved: 50M(3) US Capacity: 48M(3) SKINBIT (1) source (2) source (3) 66M americans with a history of skin cancer + 32M of 65yo+ without history of skin cancer but need an annual check = 98M, 10,000 dermatologists (excluding surgeons only) x 40 visits/day x 50% time allocation to skin checks x 240 worked day/year = 48M SkinBit: Making Early Detection Accessible to Everyone SkinBit's full-body AI scanner, under development, is being designed to capture high-resolution medical images in just 60 seconds, creating a complete skin health baseline. Our technology is designed to identify concerning spots with 90% accuracy based on internal testing and tracks changes over time, serving the 65 million Americans lacking access to timely care. Our Proprietary Scanner ☑Full body dermoscopic scanner ✔Over 90% efficiency in detecting cancer* ✔Compact design for ubiquitous deployments * based on internal testings SKINBIT Beyond Human Vision: Technology That Saves Lives Our scanner, currently in development, is being engineered to capture highly detailed full-body images in under 60 seconds, detecting subtle changes invisible to the naked eye. Our AI evaluates every spot for risk factors while building a proprietary dataset that grows more valuable with each scan. Al-Based Lesion Tracking & Assessment Image Acquisition Computer Vision Processing ↓ HIGH RESOLUTION PHOTOGRAPHY AI ENHANCED EVOLUTION TRACKING DERMOSCOPIC IMAGE AI MALIGNANCY ASSESSMENT SKINBIT Smart Regulatory Strategy: Market Entry with Clear Path to Autonomy Our two-phase regulatory approach maximizes speed to market while building toward full autonomy: 1. First, we plan to obtain 510(k) clearance as a dermatologic imaging device for our scanning hardware. 2. Initially, we will operate with dermatologist oversight of our AI analysis. 3. This human-in-the-loop model allows revenue generation while we gather performance data. 4. Once we build a robust clinical dataset, we intend to pursue FDA clearance for fully autonomous AI analysis. This strategic approach allows us to launch quickly, generate revenue, and steadily progress toward our vision of fully automated skin cancer screening. Empowering both Patients and Doctors: Better Outcomes Through Technology We're creating a data-driven approach that eliminates subjectivity from skin cancer screening. By establishing comprehensive baselines and tracking changes over time, our technology has the potential to significantly reduce both false positives and false negatives. This allows dermatologists to focus their expertise on patients with genuine risk factors. The result is a more efficient healthcare system with better outcomes for everyone involved. Improving Outcomes Through Data Dermatologists SKINBIT Healthy Needs Care False Negative False Positive SKINBIT From Clinic to Community: Redefining Access SkinBit plans to build a hybrid network combining our own flagship centers with strategic third-party locations like MedSpas and imaging centers. We deploy scanners using a zerocost "vending machine" model, eliminating upfront investment for partner clinics and enabling rapid integration into existing healthcare environments. SKINBIT SKINBI SENTINEL INBIT SKINBIT The Patient Journey Patients start with a quick 60-second full-body scan at their chosen location. Our AI immediately identifies and labels all lesions, which are then reviewed by a dermatologist. Patients receive their comprehensive results through our mobile app within a few minutes, creating a baseline digital twin of their skin health. For patients with concerning findings, the app seamlessly connects them to our dermatologist for a video consultation, who can refer them to a local practitioner. This integrated approach ensures that patients receive screening and are guided through the entire care journey, removing barriers that typically delay treatment. 1 Visit SkinBit Location 2 Get Scanneр 3 Al-Based 4 Get Your Assessment Report High-Risk Lesions Review by SkinBit Dermatologist SKINBIT Subscription-Like Revenue Model SkinBit leverages medical requirements for annual skin checks for patients with a history of skin cancer and adults aged 65 and older, creating a natural recurring revenue stream. We plan to charge $199 per scan, which may be covered by health insurance depending on the patient's coverage. Based on internal assumntions. each scanner is proiected to generate approximately $1 million annually from 20 daily scans, with retention driven by medical necessity rather than consumer preference. Targeted unit economics Scanner Production Cost $20,000 Revenues / Scanner / Year* $1.000.000 Operating Costs $378,000 Margin/ Scanner / Year $622,000 * 20 patients/day 5 days/week SKINBIT Forward-looking projections are not guaranteed. A $15 Billion Opportunity: Meeting Unmet Demand The US market alone needs 98 million screenings annually-a $15 billion opportunity. With skin cancer rates climbing and specialist shortages growing worse each year, SkinBit aims to deliver immediate screening intended to benefit a broad population in need of timely skin health assessments screening that benefits everyone: patients get life-saving early detection, providers will increase their capacity without adding staff, and investors will access untapped healthcare revenue. 98M Americans Americans need annual screening $150/screening $15B Paid by health insurance or Medicare Total Addressable Market Defensible Moats: Data, Network, Brand We believe SkinBit's business is protected by three powerful moats: SKINBIT Data Network Effect Our proprietary dataset (50,000 data points today) enhances our Al with each scan, building an accuracy advantage that competitors cannot easily match. 50K CONFIRMED CANCERS DATASET Hub & Spoke Model Our network of branded locations and partner sites creates convenient nationwide access, establishing SkinBit as a trusted skin screening leader. Brand We're building a brand solely focused on skin cancer detection, positioning SkinBit as a category-defining name patients seek out for preventive skin health. SKINBIT This combination of technology, physical presence, and focused brand identity creates a sustainable competitive advantage in the market for early skin cancer detection. Unlike competitors offering partial solutions, we believe we've created a complete platform integrating hardware, software, and clinical workflow with both quality and accessibility. SkinBit Canfield Fotofinder DermaSensor Full Body Photography 3D 3D 2D Single Lesion Full Body Dermoscopy Yes No No No Autonomous Yes No No No Cost $0 + Rev. share $500K $100K Subscription Our Traction: Building Momentum SkinBit SKINBIT ☑ Roadmap ОCTOBER 2024 Creation of a 50,000 images data set with confirmed diagnosis including Melanoma, BCC and SCC ☑ ☑ NOVEMBER 2024 Market research conducted across 135 clinics, med-spas, and imaging centers in the U.S. to validate demand SEPTEMBER 2024 Direct market testing validated demand through 3,000 patients with $199 price point achieving highest conversion ☑ FEBRUARY 2025 Π Beginning of full body scanner development AUGUST 2025 SkinBit full body scanner pre-production model ☐ OCTOBER 2025 SkinBit patient apр 口 NOVEMBER 2025 SkinBit full body scanner production model DECEMBER 2025 SkinBit physician portal DECEMBER 2025 FDA 510 (k) submission APRIL 2026 Opening of the first SkinBit center in Beverly Hills ОСТОВЕR 2026 Opening of the second SkinBit center in San Francisco 2 SKINBIT * Our dataset comprises dermatologic images with diagnoses confirmed through histopathological biopsies, built by combining publicly available resources from the International Skin Imaging Collaboration (ISIC) with privately sourced clinical images from partnering dermatology practices. Forward-looking statements are not guaranteed. Invest in Life-Saving Technology Skinbit 5 Reasons to invest ☑ BROAD MARKET 5.4M new skin cancer cases annually, 98M Americans need annual skin check ✔LIFE-CHANGING IMPACT Early detection transforms outcomes and saves lives ✔ SMART REGULATORY APPROACH Hardware clearance first, with human oversight enabling immediate revenue while building toward autonomous Al approval ☑ CAPITAL-EFFICIENT GROWTH Zero-up-front cost deployment enables rapid scaling ☑ RECURRING REVENUE MODEL Annual screenings create predictable, subscription-like income SKINBIT SkinBit combines breakthrough technology, clinical expertise, and a patient-centered mission to revolutionize how we detect and treat skin cancer. Your investment supports our work developing accessible screening technology that will save countless lives through early detection. Join us as we build a future where skin cancer is detected at its earliest, most treatable stage for everyone, not just those with privileged access to specialists. By democratizing early detection, we aim to help transform skin cancer detection into a more manageable process, potentially improving outcomes through earlier diagnosis. Be part of the revolution that puts life-saving technology into communities where it's needed most. Together, we can create a world where no one faces a delayed diagnosis because they 11 coulan't see a aermatoiogist in time. Skin health innovation for everyone, backed by everyone.

FAQ